INmune Bio, Inc.
NASDAQ:INMB
5.41 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | INmune Bio, Inc. |
Symbool | INMB |
Munteenheid | USD |
Prijs | 5.41 |
Beurswaarde | 119,953,225 |
Dividendpercentage | 0% |
52-weken bereik | 4.32 - 14.74 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raymond Joseph Tesi M.D. |
Website | https://www.inmunebio.com |
An error occurred while fetching data.
Over INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)